On January 2, 2026, Oncotelic Therapeutics, Inc. amended agreements with Jefferson Capital Ventures and CEO Vuong Trieu, lowering the market capitalization milestone from $100 million to $45 million for stock awards tied to corporate goals. This aims to facilitate future financing and uplisting efforts.